[Depakene (sodium valproate) in the treatment of epilepsy in children and adolescents: efficiency and safety].
375 patients 7 months-19 years of age with different forms of epilepsy were treated with depakine. High efficiency of the drug was found in all forms of children's epilepsy. A complete remission was observed in 60% of the patients, a good effect--in 19%, a satisfactory effect--in 15%, 6%--were non-responders. The highest efficiency of depakine was achieved in idiopathic forms of epilepsy (complete remission--in 74% of the cases) and, therefore, depakine can be used as a monotherapy. Meanwhile, the efficiency of depakine was lower in cryptogenic generalized and symptomatic partial epilepsy. In such cases depakine should be used as a basic preparation in polytherapy. Side effects were observed in 35% of the cases, but stopping of therapy was necessary only in 25% of such cases. Rare idiosyncrasy and no negative influence on the cognitive functions were important-properties of depakine.